logo

The COVID-NMA initiative
A living mapping and living systematic review of Covid-19 trials

COVID-NMA is an international research initiative supported by the WHO and Cochrane.

We provide a living mapping of COVID-19 trials available through interactive data visualizations. We are also conducting living evidence synthesis on preventive interventions, treatments and vaccines for COVID-19 to assist decision makers.

See the description of our model here and our living review protocol here.

LIVING MAPPING OF TRIALS

(i.e., trials registered on the WHO platform)
Updated weekly

2659
Randomized Trials
1411 RCTs recruiting

2191
RCTs on treatments
(1194 recruiting)

291
RCTs on prevention
(127 recruiting)

177
RCTs on vaccines
(90 recruiting)

LIVING SYNTHESIS OF PUBLISHED TRIALS

(include both articles and preprints)
Updated daily

216
RCTs with complete data extraction and results
included in our evidence synthesis

170
RCTs on treatments

8
RCTs on prevention

26
RCTs on vaccines

Weekly update

On the 1st of February 2021, the protocol of the review on pharmacological treatments was amended to consider only the following outcomes:

Critical outcomes:
  • Clinical improvement (D28 / D60 or more) defined as a hospital discharge or improvement on the scale used by trialists to evaluate clinical progression and recovery. We will describe the scale and the threshold used to define improvement where appropriate.
  • WHO Clinical Progression Score level 7 or above (i.e., Mechanical ventilation +/- additional organ support (ECMO, vasopressors or dialysis) OR death (D28 / D60 or more)
  • All-cause mortality (D28 / D60 or more)
  • Viral negative conversion (D7)
  • Incidence of any adverse events
  • Incidence of serious adverse events (SAEs)

    Important outcomes:

  • Time to clinical improvement
  • Time to WHO Clinical Progression Score level 7 or above
  • Time to death
  • Time to viral negative conversion

    Weekly update:March 1 to March 5, 2021

    • We identify and now report 5 new pharmacological trial and 2 new vaccine trials. We have also included and presently extracting additional 22 new pharmacological and preventive trials, in addition to 3 vaccine trials. We have also identified and included 11 studies evaluating non pharmacological interventions and long COVID treatments pending data extraction. Click here for details.

    Scientific publications arising from COVID-NMA Initiative

    5 articles have been published in scientific journals:

    • The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic (Boutron I et al. Annals Intern Med 2020) - Read this article
    • Research response to COVID-19 needed better coordination and collaboration: a living mapping of registered trials (Nguyen et al. J Clin Epidemiol 2020) - Read this article
    • Interventions for the treatment of COVID‐19: a living network meta‐analysis (Boutron I et al, Protocol, Cochrane Library) - Read this article
    • Interventions for the prevention and treatment of COVID‐19: a living mapping of research and living network meta‐analysis(Boutron I et al, Protocol, Cochrane Library) - Read this article
    • Changes in evidence for studies assessing interventions for COVID-19 reported in preprints: meta-research study(Oikonomidi T et al, BMC Medicine) - Read this article
  • Who is using our data?

    At least 12 institutions are using our data

    • World Health Organisation (WHO) - See details
    • UK National Institute for Health and Care Excellence (NICE) - See details
    • South African National Department of Health - See details
    • Australian National COVID-19 Clinical Evidence Taskforce - See details
    • UK National Institute for Health Research (NIHR) Complex Review Support Unit - See details
    • NATO Centre of Excellence for Military Medicine - See details
    • Hôpitaux Universitaires de Genève - See details
    • Caribbean Public Health Agency - See details
    • Austrian Institute for Health Technology Assessment - See details
    • German Council on Foreign Relations (DGAP) - See details
    • Canada's COVID-19 Clinical Pharmacology Task Group - See details
    • World Trade Organization (WTO) - See details

    Newsletter

    To receive updates on our project and research findings, please subscribe to our digest, we will share with you new RCT results and other interesting news.

    This work received some funding from the Agence Nationale de la Recherche (ANR), the World Health Organization (WHO), Cochrane France, Center of Research in Epidemiology and StatisticS (CRESS), Centre d’Epidémiologie Clinique (GHU Cochin, Hôtel Dieu, Assistance Publique Hôpitaux de Paris (APHP) and Université de Paris), Centre national de la recherche scientifique (CNRS) and the Federal Ministry of Health, Germany